Premium
Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine‐induced cognitive deficits in mice
Author(s) -
Horio Mao,
Fujita Yuko,
Hashimoto Kenji
Publication year - 2013
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2012.01045.x
Subject(s) - phencyclidine , allosteric modulator , metabotropic glutamate receptor , nmda receptor , metabotropic receptor , pharmacology , allosteric regulation , antagonist , glutamate receptor , medicine , metabotropic glutamate receptor 2 , neuroscience , chemistry , receptor , psychology
This study was undertaken to examine the effects of CDPPB (3‐cyano‐ N ‐(1,3‐diphenyl‐1 H ‐pyrazol‐5‐yl)benzamide), a positive allosteric modulator ( PAM ) of metabotropic glutamate receptor 5 (m G lu 5 ), on cognitive deficits in mice after repeated administration of the N ‐methyl‐ D ‐aspartate ( NMDA ) receptor antagonist phencyclidine ( PCP ). In the novel object recognition test, PCP (10 mg/kg/day for 10 days)‐induced cognitive deficits in mice were not improved by a single administration of CDPPB (10 mg/kg/day). However, PCP (10 mg/kg/day for 10 days)‐induced cognitive deficits in mice were significantly improved by subsequent subchronic (14 days) administration of CDPPB (10 mg/kg/day), but not of CDPPB (1.0 mg/kg/day). This study suggests that PCP ‐induced cognitive deficits in mice are improved by subsequent subchronic administration of CDPPB . Therefore, m G lu 5 PAM s would be potential therapeutic drugs for cognitive deficits in schizophrenia.